Roche Holding AG Participation (ROPC)

Currency in CHF
390.00
-2.10(-0.54%)
Delayed Data·
Trading near 52-week High
ROPC is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
388.80395.00
52 wk Range
258.20395.00
Key Statistics
Bid/Ask
390.10 / 390.20
Prev. Close
392.1
Open
395
Day's Range
388.8-395
52 wk Range
258.2-395
Volume
268.16K
Average Volume (3m)
937.08K
1-Year Change
43.6672%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ROPC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
385.66
Downside
-1.11%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

11 Buy
9 Hold
1 Sell
Ratings:
21 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 385.66
(-1.11% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Deutsche Bank
Buy500.00+28.17%340.00UpgradeOct 23, 2026
RBC Capital
Buy400.00+2.54%-MaintainOct 19, 2026
HSBC
Hold380.00-2.59%365.00MaintainSep 10, 2026
RBC Capital
Buy400.00+2.54%-New CoverageSep 09, 2026
Barclays
Buy430.00+10.23%410.00MaintainSep 08, 2026

Roche Holding AG Participation Earnings Call Summary for H2/2025

  • Roche's Q4 2025 EPS of 8.37 missed forecasts by 19.13%, while revenue exceeded expectations at 15.65 billion CHF, a 0.64% positive surprise.
  • Pharmaceutical division drove 7% group sales growth with a 9% increase to 47.7 billion CHF; core operating profit improved by 13% despite the quarterly EPS miss.
  • Management forecasts mid-single-digit sales growth and high single-digit core EPS growth for 2026, with several new molecular entities advancing to Phase 3.
  • Stock showed resilience with a 3.67% pre-market increase despite the earnings miss, reflecting investor confidence in revenue performance and pipeline potential.
  • Analysts expressed particular interest in giredestrant's market potential and fenebrutinib's prospects in multiple sclerosis treatment during the Q&A session.
Last Updated: 2026/02/03, 12:30
Read Full Transcript

Earnings

Latest Release
Oct 22, 2026
EPS / Forecast
-- / --
Revenue / Forecast
16,13B / 15,74B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -
Dividend Yield
2.50%
Industry Median 2.08%
Annualised payout
9.80
Paid annually
5-Years Growth
+1.49%
Growth Streak

ROPC Income Statement

Compare ROPC to Peers and Sector

Metrics to compare
ROPC
Peers
Sector
Relationship
P/E Ratio
0.0x21.2x−0.3x
PEG Ratio
0.000.120.00
Price/Book
0.0x2.5x2.6x
Price / LTM Sales
0.0x2.8x2.9x
Upside (Analyst Target)
0.0%−5.0%64.3%
Fair Value Upside
Unlock15.0%9.2%Unlock

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.

Employees
103249

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
223,71M28,08%87,70B
Other Institutional Investors
764,52K0,10%299,69M
Public Companies & Retail Investors
572,28M71,83%224,34B
Total
796,76M100,00%312,33B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
UBS Asset Management AG4,29%34 209 62513 410 173
BlackRock, Inc.4,28%34 121 24713 375 529

FAQ

What Is the Roche Holding Participation (ROPC) Stock Price Today?

The Roche Holding Participation stock price today is 390,00 CHF.

What Stock Exchange Does Roche Holding Participation Trade On?

Roche Holding Participation is listed and trades on the Switzerland Stock Exchange.

What Is the Stock Symbol for Roche Holding Participation?

The stock symbol for Roche Holding Participation is "ROPC."

What Is the Roche Holding Participation Market Cap?

As of today, Roche Holding Participation market cap is 311,14B CHF.

When Is the Next Roche Holding Participation Earnings Date?

Roche Holding Participation will release its next earnings report on Feb 04, 2027.

From a Technical Analysis Perspective, Is ROPC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Roche Holding Participation Stock Split?

Roche Holding Participation has split 1 times.

How Many Employees Does Roche Holding Participation Have?

Roche Holding Participation has 103249 employees.

What is the current trading status of Roche Holding Participation (ROPC)?

As of Oct 23, 2026, Roche Holding Participation (ROPC) is trading at a price of 390,00 CHF, with a previous close of 392,10 CHF. The stock has fluctuated within a day range of 388,80 CHF to 395,00 CHF, while its 52-week range spans from 258,20 CHF to 395,00 CHF.

What Is Roche Holding Participation (ROPC) Price Target According to Analysts?

The average 12-month price target for Roche Holding Participation is 385,66 CHF, with a high estimate of 440 CHF and a low estimate of 250 CHF. 11 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an -1,11% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.